Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives CHMP backing for new combination diabetes therapy

AstraZeneca receives CHMP backing for new combination diabetes therapy

31st May 2016

AstraZeneca has received a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for approval of its new diabetes therapy.

The committee has offered a positive opinion endorsing a tablet-based fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adults with type 2 diabetes.

Potentially, this could be the first DPP-4i/SGLT-2i combination product to be approved in Europe. It is intended to improve glycaemic control in cases where other therapies have not provided adequate glycaemic control, or when a patient is already being treated with a free combination of saxagliptin and dapagliflozin.

Results from three studies in type-2 diabetes have demonstrated the glycaemic control benefits associated with the new combination therapy when compared to established treatment strategies.

A final decision from the European Commission is now expected within the next few months.

This comes after AstraZeneca received a recommendation from the CHMP for its new pandemic live attenuated influenza vaccine last month.ADNFCR-8000103-ID-801819402-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.